Long COVID Dopamine Study Finds Loss of Brain Nerve Endings

PET scans of 24 long COVID patients showed fewer dopamine nerve endings in the striatum, tied to apathy and memory issues. The study is small and early.

Updated

Share this article

Home › Tech, AI and Business

A new long COVID dopamine study suggests some patients have lost dopamine-releasing nerve endings in the brain. PET scans of 24 people with long COVID in Canada showed reduced levels of a dopamine marker in the striatum compared with healthy controls, researchers reported in eBioMedicine, as ScienceAlert reported Oct. 4, 2026.

Part of our Tech, AI and Business coverage. Browse more in Science, Health and Culture.

Advertisement

What the long COVID dopamine scans found

The team used positron emission tomography with a radioactive tracer that binds a protein on dopamine nerve endings. None of the 24 participants had an active infection, but all had persistent symptoms after COVID-19. As a group, they reported a lack of motivation and scored worse on memory and movement-speed tests.

Compared with healthy people of similar age, the patients showed lower density of dopamine nerve endings in several regions of the striatum, a brain area tied to motivation, movement and memory. Lower signal tracked with more apathy, poorer memory and slower performance on movement and reading tests. ScienceAlert reported that about 25% of the variation in those symptoms was associated with the dopamine marker.

Why dopamine could be vulnerable

“Our findings provide compelling evidence that long COVID involves the loss of dopamine-releasing neurons,” psychiatrist Jeffrey Meyer of the Brain Health Imaging Center in Canada said, as quoted by ScienceAlert. Researchers have proposed two possible routes: immune cells that prune synapses, which are elevated in some long COVID patients, and direct infection of dopamine neurons by SARS-CoV-2, since those cells carry receptors the virus could use.

Limits and possible treatments

The study is small and preliminary. The scans measure a protein on nerve endings rather than counting neurons directly, and long COVID symptoms vary widely, so the findings may apply only to patients with motivation, memory or movement problems. The authors call for larger, well-controlled studies, and ScienceAlert noted that Meyer has a pending patent application for a dopamine-based long COVID treatment.

If the link holds, the authors argue, therapies that boost dopamine release, similar in approach to Parkinson’s drugs such as L-dopa, could be worth testing. They note that no current trials focus on that strategy. Such drugs carry real side effects, so patients should not self-treat.

What comes next for patients

For people with long COVID, the work adds biological evidence to symptoms that are often hard to measure. Research on new treatment platforms keeps moving, from Novartis’ Abogen mRNA deal to AI tools such as Microsoft’s Quine biology AI that aim to speed lab discovery. Funding for that kind of science is also a live issue locally, as our report on Harvard’s $150 million research push shows.

Advertisement

Sources: Liu et al., eBioMedicine (2026); ScienceAlert.

How the researchers frame the finding

According to ScienceAlert, earlier long COVID brain research mostly looked at inflammation and immune changes, and none had directly examined whether dopamine-producing neurons were affected. Meyer said, “This kind of injury is well known to produce symptoms like lack of motivation and motor slowing, and may contribute to memory difficulties in other neurological conditions,” and argued that “long COVID is, at least in part, a disorder of the brain’s dopamine system.” Those are the researchers’ interpretations of a small, preliminary dataset.

What PET scans can and cannot show

The report explains that PET scans measure a protein found on dopamine nerve endings rather than counting neurons, though the method is useful for studying brain changes in living patients. The only way to examine dopamine-releasing neurons directly is to study postmortem tissue. One small autopsy study found fewer dopamine neurons in people who died with severe COVID-19, but most were elderly and some showed early dementia signs, including one person with Parkinson’s, which confounds the results.

Why a Parkinson’s comparison is being made

If the link is confirmed, ScienceAlert says, long COVID may affect dopamine-releasing neurons in ways broadly similar to Parkinson’s disease, and drugs such as L-dopa could in theory be repurposed. The study authors write that interventions targeting these neurons “would have therapeutic impact” as a hypothesis, calling it “a notable shift from present therapeutic development, given that no current trials focus on augmenting functions of dopamine-releasing neurons.” They theorize such treatments would raise dopamine release broadly and reduce the impact of lost synapses. The report cautions these drugs carry significant side effects and should not be taken lightly, so patients should talk with a clinician rather than self-treat.

Sources


Further Reading

Read next in Science

Get The Boston Report Briefing

Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.

Free. We never sell your address. Privacy policy

Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Sign up